Ciraparantag is a small molecule featuring heterocyclic, aromatic, and polar regions that modulate binding orientation and electronic distribution. Researchers use it to explore noncovalent interaction networks, conformational constraints, and solvation dynamics. Its structure supports mechanistic modeling and ligand-engineering approaches.
CAT No: R2256
CAS No:1438492-26-2
Synonyms/Alias:Ciraparantag;1438492-26-2;PER-977;Aripazine;Ciraparantag [USAN];PER977;UNII-U2R67KV65Q;U2R67KV65Q;Ciraparantag (USAN);PER 977;CIRAPARANTAG [INN];CIRAPARANTAG [WHO-DD];N1,N1'-(Piperazine-1,4-diylbis(propane-1,3-diyl))bis-L-argininamide;1438492-26-2 (free base);(2S)-2-amino-N-[3-[4-[3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propyl]piperazin-1-yl]propyl]-5-(diaminomethylideneamino)pentanamide;Pentanamide, N,N'-(1,4-piperazinediyldi-3,1-propanediyl)bis(2-amino-5-((aminoiminomethyl)amino)-, (2S,2'S)-;(2S,2'S)-N,N'-(piperazine-1,4-diylbis(propane-3,1-diyl))bis(2-amino-5-guanidinopentanamide);(2S)-2-amino-N-[3-(4-{3-[(2S)-2-amino-5-carbamimidamidopentanamido]propyl}piperazin-1-yl)propyl]-5-carbamimidamidopentanamide;Ciraparantag(PER977);ciraparantagum;(2S)-2-amino-N-(3-(4-(3-((2S)-2-amino-5-carbamimidamidopentanamido)propyl)piperazin-1-yl)propyl)-5-carbamimidamidopentanamide;Pentanamide, N,N'-(1,4-piperazinediyldi-3,1-propanediyl)bis[2-amino-5-[(aminoiminomethyl)amino]-, (2S,2'S)-;Ciraparantag(PER977)?;CHEMBL3544919;SCHEMBL14985871;CHEBI:230136;DTXSID701045783;AKOS030526536;CS-5640;DB15199;DA-51926;HY-18660;D10868;Q27290602;
Ciraparantag is a synthetic small molecule compound recognized for its unique biochemical role as a reversal agent for certain anticoagulants. Structurally characterized by its polycationic nature, Ciraparantag interacts with a range of direct oral anticoagulants and heparin derivatives through non-covalent binding. Its capacity to modulate the activity of these agents has made it a focal point in anticoagulation research, particularly in studies seeking to understand and control blood coagulation pathways. As a versatile research tool, Ciraparantag offers valuable insights into the mechanisms of drug reversal and the broader pharmacodynamics of anticoagulant agents.
Anticoagulation reversal research: Ciraparantag is widely employed in laboratory studies focused on the reversal of anticoagulant activity. Researchers use it to investigate the mechanisms by which direct oral anticoagulants and low molecular weight heparins can be neutralized in vitro. By introducing Ciraparantag into experimental models, scientists are able to observe its interactions with various anticoagulant molecules, enabling the evaluation of binding affinities, kinetics, and the effectiveness of reversal under controlled biochemical conditions.
Pharmacodynamic modeling: The compound serves as a critical reagent in the development of pharmacodynamic models that simulate anticoagulant reversal. In these studies, Ciraparantag is utilized to assess dose-response relationships, time-dependent effects, and the restoration of coagulation parameters in plasma or whole blood systems. Such modeling supports the optimization of dosing strategies and enhances the understanding of the interplay between reversal agents and anticoagulant drugs at the molecular and systemic levels.
Analytical method development: Ciraparantag is instrumental in the validation and refinement of analytical assays designed to detect and quantify anticoagulant activity. Its use allows for the establishment of assay sensitivity and specificity by providing a reliable means to modulate anticoagulant effects in test samples. Researchers leverage its properties to calibrate laboratory protocols, ensuring accurate measurement of anticoagulant concentrations and the efficacy of reversal processes in both basic and applied biochemical research.
Drug interaction studies: The polycationic characteristics of Ciraparantag make it a valuable probe in studies examining the interaction between reversal agents and a broad spectrum of anticoagulant drugs. Experimental investigations utilize the compound to explore binding mechanisms, competitive inhibition, and potential interference with other pharmacological agents. These studies contribute to a comprehensive understanding of drug-drug interactions and inform the design of safer anticoagulation management protocols in research settings.
Mechanistic exploration of coagulation pathways: Ciraparantag provides researchers with an effective tool for dissecting the complex pathways involved in blood coagulation and anticoagulant pharmacology. By modulating the activity of specific anticoagulants, it enables detailed analysis of the molecular events governing clot formation and dissolution. Such mechanistic studies are critical for elucidating the roles of various coagulation factors, enhancing the scientific community's ability to develop targeted strategies for anticoagulant reversal and the management of bleeding risks in experimental models.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More